The company behind
the technology
Learn about our story, meet the team, explore the latest news, and find the resources you need.
About Us
Empowerment through proven science
Control Bionics is a neurotechnology company delivering objective, measurable outcomes through non-invasive, neural-signal technology, proven today and built to scale for the future.
Our platform is grounded in surface EMG expertise, combined with software capability, medical-device validation, and proven use in complex clinical environments. It is deployed across performance, rehabilitation, research, and assistive communication applications, cleared by the FDA, TGA, and CE, and active in markets across Australia, the United States, Canada, and Japan.
We exist to advance human potential through neural-signal innovation, delivering outcomes today and enabling new applications tomorrow.
The people, the science, and the story behind the company
Built on science. Driven by what the technology makes possible. Select a section to explore.
Our Story →
Two decades of EMG science, a founder’s vision, and the platform that grew from a single insight.
Board of Directors →
The Directors overseeing Control Bionics’ growth and governance.
Team →
Meet the operational leadership team behind the platform.
News →
The latest platform developments, clinical announcements, and company updates.
Resources →
Research publications, technical documentation, training materials, and clinical resources.
Careers →
Join a focused, global team building technology that changes what is possible.
How we work.
Principle - Validated, not speculative
The technology is grounded in medical-device science and proven in complex clinical environments. Not conceptual. Not emerging. Deployed today.
Principle — Technology-led, not product-defined
The neural-signal technology is the constant. Applications and products evolve around it. The data capability endures.
Principle — Outcomes over claims
Every application of the technology is measured against real-world results. Measurable outcomes and decision-ready data, not generic benefits.